Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 11/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12544010 | 1.00 | ALOX5 (0.40) | ALOX5KDRHDAC3FLT1HDAC6 | |
| SCHEMBL2195228 | 0.89 | ALOX5 (0.42) | ALOX5KDRHDAC3FLT1HDAC6 | |
| SCHEMBL2175935 | 0.88 | ALOX5 (0.43) | ALOX5KDRHDAC3FLT1HDAC6 | |
| SCHEMBL2178270 | 0.88 | ALOX5 (0.43) | ALOX5KDRHDAC3FLT1HDAC6 | |
| SCHEMBL28093003 | 0.86 | HDAC3 (0.39) | ALOX5HDAC3ANO1 | |
| SCHEMBL12544634 | 0.84 | MET (0.42) | KDR | |
| SCHEMBL30779385 | 0.84 | MET (0.42) | KDR | |
| SCHEMBL12489601 | 0.83 | KDR (0.36) | ALOX5KDRFLT1AURKARPS6KB1 | |
| SCHEMBL12544009 | 0.80 | DOT1L (0.41) | ALOX5 | |
| SCHEMBL2177207 | 0.79 | MAPT (0.42) | ALOX5KDRHDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | ALOX5 989/4885KDR 513/4885HDAC3 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.